Alternatives to Elahere If You Can't Fill Your Prescription

Elahere (mirvetuximab soravtansine-gynx) is a first-in-class treatment for platinum-resistant ovarian cancer, but not every patient can access it right away. Some patients may not qualify due to FRα expression levels; others face insurance delays, infusion center access issues, or are currently unable to tolerate an ADC. If you're in this situation, it's important to know what alternatives exist. This is not a decision to make on your own — always work closely with your gynecologic oncologist to choose the best path for your specific situation.

Why Patients May Need an Alternative to Elahere

Tumor does not express sufficient FRα levels (tested negative on VENTANA FOLR1 assay)

Insurance denial or prior authorization delay

Pre-existing corneal disease or Grade >1 peripheral neuropathy that may worsen with Elahere

Disease progression on Elahere and need for a new regimen

No access to an infusion center within a reasonable distance

Standard Chemotherapy Options for Platinum-Resistant Ovarian Cancer

Before Elahere received FDA approval in 2022, these non-platinum chemotherapy agents were the standard of care for platinum-resistant ovarian cancer (PROC). They remain options for patients who cannot receive Elahere:

1. Paclitaxel (Taxol)

Weekly paclitaxel is one of the most commonly used chemotherapy agents in PROC. As a single agent, it produces objective response rates of roughly 10–13%. It can be combined with bevacizumab for improved PFS. Side effects include peripheral neuropathy, hair loss, and fatigue. Generics are widely available, making it far more affordable than Elahere.

2. Pegylated Liposomal Doxorubicin (PLD / Doxil)

PLD (brand name Doxil in the US) is another standard option for PROC with single-agent ORRs of approximately 10–13%. It is given every 4 weeks and is notable for causing less hair loss than traditional doxorubicin, though it can cause hand-foot syndrome (palmar-plantar erythrodysesthesia) and mucositis. PLD has a history of supply shortages in the US, so ask your pharmacy about availability.

3. Topotecan (Hycamtin)

Topotecan is a topoisomerase I inhibitor available as both IV and oral formulations. It's an option in PROC but is associated with significant hematologic toxicity, including low blood cell counts (myelosuppression), which often requires dose adjustments. ORR as a single agent is similar to PLD (~10–13%).

4. Bevacizumab (Avastin) + Chemotherapy

Bevacizumab is an anti-VEGF monoclonal antibody that can be added to paclitaxel, PLD, or topotecan in PROC. The AURELIA trial showed that adding bevacizumab to chemotherapy improved median PFS to 6.7 months (vs 3.4 months with chemotherapy alone) and ORR to 30.9%. Bevacizumab does not require companion diagnostic testing, making it available to all eligible PROC patients regardless of FRα status. However, it has not shown an overall survival benefit in PROC and carries risks including hypertension, GI perforation, and thrombosis.

5. Gemcitabine (Gemzar)

Gemcitabine is an IV chemotherapy with modest single-agent activity in PROC. It is sometimes used when patients have exhausted other options or when neuropathy from paclitaxel is a concern. Generic gemcitabine is widely available.

6. Relacorilant (Lifyorli) + Nab-Paclitaxel — New in 2026

In March 2026, the FDA approved relacorilant (Lifyorli) in combination with nab-paclitaxel (Abraxane) for patients with platinum-resistant ovarian cancer who have received up to three prior lines of therapy, including bevacizumab. Unlike Elahere, relacorilant is biomarker-agnostic — it does not require FRα testing. It is a first-in-class selective glucocorticoid receptor antagonist. This is a new option worth discussing with your oncologist.

Clinical Trials: An Important Consideration

For patients with platinum-resistant ovarian cancer who have exhausted approved options, clinical trials may offer access to investigational ADCs, immunotherapy, and targeted agents. Ask your oncologist to check ClinicalTrials.gov for open trials in your area, particularly studies evaluating next-generation ADCs targeting FRα, HER2, or CDH6.

How medfinder Can Help If Access Is Your Main Barrier

If your primary challenge is simply finding an infusion center that carries and administers Elahere — rather than a clinical reason to switch — medfinder can help. medfinder is a paid service that calls pharmacies and infusion centers on your behalf to locate your prescription. Before switching to a less effective alternative, it's worth exploring whether the access barrier can be resolved.

See also: How to Find Elahere In Stock Near You (Tools + Tips).